http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 30 Jun 2025 16:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/Press+Releases/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >Bergen, Norway</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >Oslo, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately <money>NOK 130 million</money>, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters http://www.streetinsider.com/PRNewswire/Announcement+of+fully+underwritten+rights+issue/24998751.html Mon, 30 Jun 2025 16:36:00 -0400 A.24394000 A.34669080 A.60012005 BGBIO O.00563233 O.00871851 O.54272833 ONCIN http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 30, 2025</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), where BerGenBio will be the acquiring entity.</p> <p>Following the Merger, the combined company shall carry out a fully underwritten rights issue.</p> <ul type="disc"><li>The Merger puts BerGenBio's capital and listing to productive use by strengthening Oncoinvent's ability to execute on its clinical strategy and advance potentially life-changing treatments for patients with cancer in the http://www.streetinsider.com/Press+Releases/BerGenBio+and+Oncoinvent%2C+a+rising+innovator+in+radiopharmaceutical+cancer+therapies%2C+announce+proposed+merger+and+a+fully+underwritten+rights+issue/24998559.html Mon, 30 Jun 2025 16:28:00 -0400 A.24394000 A.28101156 A.50200201 A.60012005 BGBIO O.00465543 O.00871851 O.05214470 O.54272833 ONCIN OSAKA